The cognitive restoration effects of Picamilon® Ginkgo in patients with non-amnestic mild cognitive impairment (results of a comparative cohort study)

Introduction. The concept of mild cognitive impairment (MCI) serves as a useful diagnosis for clinicians, enabling careful monitoring and extensive potential for therapeutic interventions. The phenotypic classification of MCI allows to identify the probable cause of MCI and predict its development.

Aim. To evaluate the effect of a 12-week (3-month) therapy course with Picamilon® Ginkgo on restoration of cognitive functions in patients with the non-amnestic MCI phenotype.

Materials and methods. The treatment group included 21 patients receiving Picamilon® Ginkgo as part of combination therapy. The comparison group included 25 patients receiving only stable combination therapy aimed to manage vascular risks. Cognitive impairment was diagnosed and assessed at baseline and at 12 weeks (3 months) of stable therapy using the MoCA test to determine total MoCA sores (MoCA-Total), MoCA-MIS, and MoCA domain-specific index scores: executive function, attention, and visual-constructive skills.

Results. After treatment, the mean MoCA-total score was significantly higher in the group of patients who additionally received Picamilon® Ginkgo as compared to the patients receiving vascular risk reduction therapy alone (26.8 ± 1.1 versus 25.3 ± 1.3 points, p < 0.05). Among patients randomized to Picamilon® Ginkgo group, 47.6% returned back to normal cognitive function (MoCA-total ≥26 points) scores versus 20.0% of patients in the comparison group (χ² = 3.962, p < 0.05).

Conclusion. The combination agent Picamilon® Ginkgo is an effective, safe, and promising treatment for vascular cognitive impairment, including the potential for reversion to normal cognitive function.

1. Overton M, Pihlsgård M, Elmståhl S. Prevalence and Incidence of Mild Cognitive Impairment across Subtypes, Age, and Sex. Dement Geriatr Cogn Disord. 2019;47(4–6):219–232. https://doi.org/10.1159/000499763.

2. Etgen T, Sander D, Bickel H, Förstl H. Mild Cognitive Impairment and Dementia: The Importance of Modifiable Risk Factors. Dtsch Arztebl Int. 2011;108(44):743–750. https://doi.org/10.3238/ARZTEBL.2011.0743.

3. Chen PH, Cheng SJ, Lin HC, Lee CY, Chou CH. Risk Factors for the Progression of Mild Cognitive Impairment in Different Types of Neurodegenerati ve Disorders. Behav Neurol. 2018;2018:6929732. https://doi.org/10.1155/2018/6929732.

4. Kasper S, Bancher C, Eckert A, Förstl H, Frölich L, Hort J et al. Management of mild cognitive impairment (MCI): The need for national and international guidelines. World J Biol Psychiatry. 2020;21(8):579–594. https://doi.org/10.1080/15622975.2019.1696473.

5. Salemme S, Lombardo FL, Lacorte E, Sciancalepore F, Remoli G, Bacigalupo I et al. The prognosis of mild cognitive impairment: A systematic review and meta‐analysis. Alzheimers Dement. 2025;17(1):e70074. https://doi.org/10.1002/dad2.70074.

6. Kaur A, Edland SD, Peavy GM. The MoCA-Memory Index Score An Efficient Alternative to Paragraph Recall for the Detection of Amnestic Mild Cognitive Impairment. Alzheimer Dis Assoc Disord. 2018;32(2):120–124. https://doi.org/10.1097/wad.0000000000000240.

7. Ghosh S, Libon D, Lippa C. Mild Cognitive Impairment: A Brief Review and Suggested Clinical Algorithm. Am J Alzheimers Dis Other Demen. 2014;29(4):293–302. https://doi.org/10.1177/1533317513517040.

8. Aisen PS, Jimenez-Maggiora GA, Rafii MS, Walter S, Raman R. Early-Stage Alzheimer Disease: Getting Trial-Ready. Nat Rev Neurol. 2022;18(7):389–399. https://doi.org/10.1038/s41582-022-00645-6.

9. Zaharov VV, Borodulina IV, Vakhnina NV. Treatment of patients with chronic cerebral ischemia: experience of using the combined neuroprotective drug Picamilon Ginkgo. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2022;122(9):95–103. (In Russ.) https://doi.org/10.17116/jnevro202212209195.

10. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–699. https://doi.org/10.1111/j.1532-5415.2005.53221.x.

11. Julayanont P, Brousseau M, Chertkow H, Phillips N, Nasreddine ZS. Montreal Cognitive Assessment Memory Index Score (MoCA-MIS) as a predictor of conversion from mild cognitive impairment to Alzheimer’s disease. J Am Geriatr Soc. 2014;62(4):679–684. https://doi.org/10.1111/jgs.12742.

12. Ngandu T, Lehtisalo J, Solomon A, Levalahti E, Ahtiluoto S, Antikainen R et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255–2263. https://doi.org/10.1016/S0140-6736(15)60461-5.

13. Koepsell TD, Monsell SE. Reversion from mild cognitive impairment to normal or near-normal cognition: risk factors and prognosis. Neurology. 2012;79(15):1591–1598. https://doi.org10.1212/WNL.0b013e31826e26b7.

14. Zuo W, Yan F, Zhang B, Li J, Mei D. Advances in the studies of ginkgo biloba leaves extract on aging-related diseases. Aging Dis. 2017;8(6):812–826. https://doi.org/10.14336/AD.2017.0615.

15. Xie L, Zhu Q, Lu J. Can we use Ginkgo biloba extract to treat Alzheimer’s disease? Lessons from preclinical and clinical studies. Cells. 2022;11(3):479. https://doi.org/10.3390/cells11030479.

16. Shi C, Zhao L, Zhu B, Li Q, Yew DT, Yao Z, Xu J. Protective effects of Ginkgo biloba extract (EGb761) and its constituents quercetin and ginkgolide B against beta-amyloid peptide-induced toxicity in SH-SY5Y cells. Chem Biol Interact. 2009;181(1):115–123. https://doi.org/10.1016/j.cbi.2009.05.010.

17. Xu J, Wang K, Cao Z, Cao L, Wang Z, Xiao W Antagonistic effect of ginkgolide homologues on PAF-induced platelet aggregation and neuroprotective effect. Zhongguo Zhong Yao Za Zhi. 2017;42(24):4716–4721. https://doi.org/10.19540/j.cnki.cjcmm.2017.0206.

18. Abdel-Kader R, Hauptmann S, Keil U, Scherping I, Leuner K, Eckert A, Müller WE. Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761). Pharmacol Res. 2007;56(6):493–502. https://doi.org/10.1016/j.phrs.2007.09.011.

19. Yoshitake T, Yoshitake S, Kehr J. The ginkgo biloba extract Egb 761 and its main constituent flavonoids and ginkgolides increase extracellular dopamine levels in the rat prefrontal cortex. Brit J Pharmacol. 2010;159(3):659–668. https://doi.org/10.1111/j.1476-5381.2009.00580.x.

20. Kristofikova Z, Benesova O, Tejkalova H. Changes of highaffinity choline uptake in the hippocampus of old rats after long-term administration of two nootropic drugs (Tacrine and Ginkgo biloba extract). Dementia. 1992;3:304–307. https://doi.org/10.1159/000107030.

21. Silkina IV, Ganʹshina TS, Seredenin SB, Mirzoyan RS. Gabaergic mechanism of cerebrovascular and neuroprotective effects of afobazole and picamilon. Eksperimentalnaya i Klinicheskaya Farmakologiya. 2005;68(1):2–24. (In Russ.) Available at: https://www.ekf.folium.ru/index.php/ekf/article/view/1082.

22. Das T, Saha SC, Sunita K, Majumber M, Ghorai M, Mane AB et al. Promising botanical-derived monoamine oxidase (MAO) inhibitors: pharmacological aspects and structure-activity studies. South African Journal of Botany. 2022;146:127–145. https://doi.org/10.1016/j.sajb.2021.10.024.

23. Mei N, Guo X, Ren Z, Kobayashi D, Wada K, Guo L. Review of Ginkgo bilobainduced toxicity, from experimental studies to human case reports. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2017;35(1):1–28. https://doi.org/10.1080/10590501.2016.1278298.

24. Hecker H, Johannisson R, Koch E, Siegers CP. In vitro evaluation of the cytotoxic potential of alkylphenols from Ginkgo biloba L. Toxicology. 2002;177(2-3):167–177. https://doi.org/10.1016/s0300-483x(02)00189-0.

25. Koch E, Jaggy H, Chatterjee SS. Evidence for immunotoxic effects of crude Ginkgo biloba L. leaf extracts using the popliteal lymph node assay in the mouse. Int J Immunopharmacol. 2000;22(3):229–236. https://doi.org/10.1016/s0192-0561(99)00080-6.